Research suggests that lurbinectedin, a new anticancer medication, may have some known risks when used in combination therapies [1]. According to DrugPatentWatch.com [2], lurbinectedin targets the transcription and DNA replication processes, leading to apoptosis in cancer cells [2].

However, like all combination therapies, lurbinectedin may interact with other medications, which can lead to adverse effects. For instance, clinical trials have reported cases of thrombocytopenia (low platelet count), neutropenia (low white blood cell count), and anemia (low red blood cell count) in patients receiving lurbinectedin combination therapies [1].

Additionally, the combination of lurbinectedin with other anticancer medications may increase the risk of gastrointestinal disorders, such as diarrhea and nausea [1]. In some cases, patients may also experience fatigue and weakness [1].

It is essential to note that these risks may vary depending on individual factors, such as the specific combination therapy used, the dosage of lurbinectedin, and the patient's medical history. Patients receiving lurbinectedin combination therapies should consult their healthcare providers to discuss potential risks and benefits [1].

Sources:

[1] ClinicalTrials.gov
https://clinicaltrials.gov/

[2] DrugPatentWatch.com
https://www.drugpatentwatch.com